This test is used to diagnose myotonic muscular dystrophy, which causes muscles to stay contracted for an abnormally long time. Facioscapulohumeral muscular dystrophy (FSH MD) begins in adolescence or ...

Johnny Quintana’s life changed at the age of 19 when he was diagnosed with a rare form of muscular dystrophy called ...

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic condition that affects muscle function, often making everyday tasks — like smiling or lifting one’s arms — difficult. For ...

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic condition that affects muscle function, often making everyday tasks — like smiling or lifting one’s arms — difficult. For individuals ...

The Muscular Dystrophy Association (MDA) is honoring a longtime researcher and an LGMD patient advocate with its 2025 Legacy ...

Muscular dystrophy can appear in infancy up to middle age or later, and its form and severity are determined in part by the age at which it occurs. Some types of muscular dystrophy typically ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to DYNE-101, a treatment candidate for myotonic dystrophy type 1 (DM1) — in which disease symptoms begin during adulthood ...

Dystrophy is any condition in which a part of the body weakens or wastes away. In muscular dystrophy, the weakness is in the muscles. An inherited genetic mistake prevents the body from making a ...

candidate for myotonic dystrophy type 1 (DM1), and del-brax for facioscapulohumeral muscular dystrophy (FSHD). All three candidates are based on the same TfR1-targeting antibody component.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 ...